BMS Drug Trials on Zeposia: A New Hope for Inflammatory Bowel Disease?

Matias Lopez Carrete


 BMS Drug Trials on Zeposia: A New Hope for Inflammatory Bowel Disease?

Inflammatory Bowel Disease (IBD) is a chronic condition that affects millions of people worldwide, causing painful symptoms like abdominal cramps, diarrhea, and fatigue. It includes disorders such as Crohn’s disease and ulcerative colitis (UC), both of which involve long-term inflammation of the digestive tract. Treating these diseases can be tricky, but pharmaceutical companies like Bristol Myers Squibb (BMS) are working hard to develop new, effective medications. One of their promising drugs is Zeposia (ozanimod), an oral treatment that has shown potential in treating IBD, particularly ulcerative colitis. However, like all drugs, Zeposia has gone through rigorous clinical trials to prove its effectiveness and safety. Let’s take a closer look at how this drug has performed in BMS’s trials.


How Does Zeposia Work?

Zeposia is an immunomodulator, meaning it works by affecting the immune system. Specifically, it targets a receptor called sphingosine-1-phosphate (S1P), which helps regulate immune cell movement. By blocking certain immune cells from attacking the digestive tract, Zeposia reduces inflammation and helps relieve symptoms of UC. This mechanism is different from older treatments like steroids and biologics, making it an attractive option for patients who don’t respond well to traditional therapies (BMS, 2024).


Success in Ulcerative Colitis Trials

BMS conducted a major Phase 3 clinical trial called True North to test the effectiveness of Zeposia in treating moderately to severely active ulcerative colitis (ClinicalTrials.gov). The results were promising—patients who took Zeposia experienced significantly higher rates of clinical remission, meaning their symptoms improved or disappeared compared to those who took a placebo. Additionally, patients showed improved mucosal healing, which is a key indicator that the drug was reducing inflammation in the intestines (GastroEndoNews, 2021).

Due to the success of True North, the FDA approved Zeposia for ulcerative colitis in 2021. This was a big deal because it introduced an oral alternative to existing treatments, which often require injections or infusions. For many patients, taking a pill is much more convenient and can improve their quality of life (BMS, 2024).


Challenges in Crohn’s Disease Trials

After seeing success in ulcerative colitis, BMS hoped Zeposia would also work for Crohn’s disease, another major type of IBD. To test this, they launched the YELLOWSTONE clinical trial program. Unfortunately, the results were not as promising. In a 2024 update, BMS announced that the first Phase 3 YELLOWSTONE trial did not meet its primary endpoint—which means that Zeposia did not show significant improvement in Crohn’s disease patients compared to a placebo (BMS, 2024).

While this was disappointing, it highlights an important part of the drug development process: not every treatment works for every condition. Crohn’s disease is more complex than ulcerative colitis because it can affect any part of the digestive tract and has different underlying mechanisms. Despite this setback, researchers are continuing to analyze the data to see if there are specific groups of Crohn’s patients who might still benefit from Zeposia.


What’s Next for Zeposia and BMS?

Even though the Crohn’s disease trials didn’t go as planned, Zeposia remains a valuable treatment for ulcerative colitis. BMS is also exploring other potential uses for the drug in different autoimmune conditions, like multiple sclerosis. The company is committed to further research and improving IBD treatments, so we may see new developments in the future (BMS, 2024).


Final Thoughts

The story of Zeposia highlights both the successes and challenges of developing new medications. Thanks to BMS’s clinical trials, thousands of ulcerative colitis patients now have access to an effective oral treatment. At the same time, the disappointing results in Crohn’s disease remind us that scientific progress is never a straight path. As research continues, there is hope that future discoveries will bring even better solutions for people living with IBD.

For now, Zeposia stands as a major step forward in the fight against ulcerative colitis, offering new hope to those who need it most.

 

 

 

 

 

 

 

 

 

 

 

 

Works Cited

Bristol Myers Squibb. “Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial.” BMS Newsroom, 2024. https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Provides-Update-on-the-First-Phase-3-YELLOWSTONE-Trial.

Bristol Myers Squibb. “FDA Approves Zeposia for Ulcerative Colitis.” BMS Newsroom, 2024. https://news.bms.com.

“FDA Approves Zeposia for Treatment of Ulcerative Colitis.” GastroEndoNews, 2021. https://www.gastroendonews.com/FDA-Update-and-Product-News/Article/06-21/FDA-Approves-Zeposia-for-Treatment-of-Ulcerative-Colitis/63725.

“True North Clinical Trial.” ClinicalTrials.gov. https://clinicaltrials.gov.

Comments

Post a Comment

Popular posts from this blog

Molecules, Models, and Magic: The Exciting World of Computational Chemistry

Vrinda Modi I often spend time in a little cubicle in McLean in the freezing corporate cold wrapped in a blanket in the Hoboken summers sipping on free coffee from the office above. It almost always tastes like chalk, but the routine is so embedded in me. Hence, this is the perfect opportunity to talk a little more about my research in computational chemistry here at Stevens and the advances I expect in the next few years. This field excites me because it bridges my interest in chemistry with modern computing techniques, a powerful tool for advancing our understanding of chemical reactions and molecular interactions. This means we are a dry lab – running simulations on computers. No chemicals, no PPE, just models and algorithms. But why does computational chemistry exist in the first place, especially when chemistry is so rooted in physical matter? The answer is efficiency. Modeling molecules on a computer saves us from ordering chemicals, waiting for deliveries (a delay in chemistry t...
Read more

Scaling the Potential of Vertical Farming Going into 2025 and Beyond

Image
  Matthew P Kearney Scaling the Potential of Vertical Farming Going into 2025 and Beyond      Vertical farming may seem like something out of a futuristic movie, but they are very real in today’s agricultural industry. Vertical farming may promote a stronger relationship between urbanization and sustainable crop production. Based on recent innovations across agriculture and technology, vertical farming has the potential to revolutionize our current farming system. Through the development of vertical farming-based production lines, cities and otherwise unfarmable areas can be provided with fresh, local, and pesticide-free produce. Vertical farming and other adaptations of agriculture are not new ideas, but instead a historic and human process.      These technologies are ready to meaningfully address global food security through the technological and computational advancements in agriculture. Vertical farming has a promising future, which becomes a case...
Read more

Knot Your Average Problem: How do Tongue Ties Impact Oral Myofunctional Health?

Image
  Hadia Hussain      Knot Your Average Problem: How do Tongue Ties Impact Oral Myofunctional Health? Sitting in the nursery of the dental office where I worked, I reviewed Baby V’s medical history and reports from the Emergency Department at Jersey City Medical Center. I found it odd that, despite multiple visits and clear signs of malnutrition, no physician had been able to diagnose the cause. Baby V, at a low weight of 12 pounds was struggling with difficulty nursing and bottle feeding, excessive gassiness, colic, clicking sounds when feeding, milk dribbling out of the mouth, and mouth breathing—but doctors had dismissed these signs, labeling him as "healthy."  It didn’t make sense as his low weight raised serious concerns.  According to Pediatric specialists Jenny Olson, DNP, and Sarha DeVrieze, ARNP, at the UnityPoint Clinic, a 9-month-old baby boy should weigh anywhere in between the range of 17 to 25 pounds. Baby V's situation was clearly a ...
Read more